Condition: Netherton Syndrome · Sponsor: Quoin Pharmaceuticals
This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.
This description comes directly from the study's public registry record.
TI Clinical Research · 858-571-1800 · clinicalresearch@therapeuticsinc.com
Oleg G Khatsenko, Ph.D · 858-571-1800 · okhatsenko@therapeuticsinc.com
Always discuss trial participation with your own doctor first.
| Center for Dermatology Clinical Research | Fremont, California, United States | Recruiting |
| Yale University School of Medicine | New Haven, Connecticut, United States | Not Yet Recruiting |
| Dawes Fretzin Clinical Reseacrh Group | Indianapolis, Indiana, United States | Recruiting |
| Beacon Clinical Research | Quincy, Massachusetts, United States | Recruiting |
| Texas Dermatology and Laser Specialists | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07538583